PAVmed Names Chief Commercial Officer

PAVmed Inc., a highly differentiated, multiproduct medical device company, has named Shaun M. O’Neil  as its first chief commercial officer. O’Neil will oversee all aspects of the domestic and international commercialization of PAVmed’s products including sales and marketing, clinician engagement and professional education. He will report directly to Lishan Aklog, M.D., PAVmed’s chairman and CEO.
 
“I am incredibly excited to welcome Shaun O’Neil to the PAVmed team,” said Aklog. “As PAVmed approaches important regulatory and commercial milestones, the time has come to begin laying the foundation for our transition from a development-stage to a commercial-stage company. I am confident Shaun is the best person to lead this effort. Dr. Brian deGuzman, PAVmed’s chief medical officer, Michael Glennon, our vice chairman, and I have been direct witnesses to Shaun’s industry savvy, leadership skills, vision, work ethic, professionalism, and integrity since AngioDynamics first joined us in discussions that led to its acquisition of our first company, Vortex Medical, and its life-saving AngioVac device.”
 
O’Neil brings to PAVmed more than 15 years of sales and marketing leadership, and product and business development expertise in both startup and established companies, including a track record in growing sales and increasing market share for innovative medical devices. Since 2011, O’Neil has held various sales and marketing leadership positions with AngioDynamics, a provider of medical devices used by interventional radiologists, interventional cardiologists, surgeons, and other physicians for the minimally-invasive diagnosis and treatment of cancer and peripheral vascular disease. Most recently O’Neil served as regional sales manager for its peripheral vascular division, where he oversaw multiple territory managers and clinical specialists. He was responsible for multiple product launches and was a perennial recipient of sales and performance awards.
 
Prior to AngioDynamics, O’Neil served in various sales, marketing, and engineering roles at Aycan Medical Systems, a privately-held medical imaging company.
 
“I have watched with keen interest as this company has made progress since its founding by a team that I learned to respect and admire over several years of working closely on the commercialization of AngioVac,” said O’Neil. “I am very excited to join PAVmed as it approaches the expected commercial launch of two products with billion-dollar market opportunities. I accepted Dr. Aklog’s offer to join this team because I have been a true believer in its vision and business model since its inception, and because I believe the company’s lead products have all the hallmarks of commercial blockbusters that will benefit many patients worldwide while creating significant value for PAVmed’s shareholders. “
 
O’Neil has a bachelor of science degree in management information systems from Alfred University and an M.B.A. from the Rochester Institute of Technology.
 
“I have spent a substantial part of my career providing physicians and their patients with less invasive and more cost-effective solutions for unmet clinical needs,” O’Neil added. “In CarpX and EsoCheck, I see two products with great potential to transform the care of patients with highly prevalent and debilitating or life-threatening conditions. PAVmed has the cash runway and streamlined business model that I believe will allow us to build tailored commercialization platforms for each product that will be ready to activate upon regulatory clearance.”
 
 
“AngioVac is a challenging device to commercialize, with multiple specialty call points and the need for intense clinical support. Shaun played a critical role in establishing a vision and plan for AngioVac’s commercialization and successfully executed on that plan with his team,” Aklog said. “We observed that he is equally as comfortable in the board room crafting strategy as he is in the trenches with his sales reps calling on physicians and hospitals to adopt a new, groundbreaking technology for the benefit of their patients. That professional versatility, drive to excel and commitment to patients aligns perfectly with our business model and company ethos.”
 
PAVmed Inc. employs a unique business model designed to advance innovative products to commercialization much more rapidly and with significantly less capital than the typical medical device company. This proprietary model enables PAVmed to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation. PAVmed’s pipeline of products address unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Its three lead products provide approaches to carpal tunnel syndrome (CarpX), precancerous conditions of the esophagus (EsoCheck), vascular access (PortIO) and pediatric ear infections (DisappEAR). The New York, N.Y.-based company is also developing products in other areas such as medical infusions and tissue ablation, while seeking to further expand its pipeline through engagements with clinician innovators and leading academic medical centers.